A 2-Step Mechanism of Arterial Thrombus Formation Induced by Human Atherosclerotic Plaques

Journal of the American College of Cardiology

Volumn 55, Issue 11, 2010, Pages 1147-1158

  Reininger, Armin J ^a   Bernlochner, Isabell ^a   Penz, Sandra M ^a   Ravanat, Catherine ^b   Smethurst, Peter ^c   Farndale, Richard W ^c   Gachet, Christian ^b   Brandl, Richard ^d   Siess, Wolfgang ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Clinic Schwabing   (Germany)

Author keywords

aggregation; atherothrombosis; collagen; fibrin; glycoprotein VI; plaque; platelet; thrombin; tissue factor

Indexed keywords

BLOOD CLOTTING FACTOR 11A; CALCIUM; COLLAGEN; FIBRIN; GLYCOPROTEIN VI; MAGNESIUM; THROMBIN; THROMBOPLASTIN;

ARTERY BLOOD FLOW; ARTERY THROMBOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENDARTERECTOMY; HUMAN; MICROSCOPY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

ATHEROSCLEROSIS; COLLAGEN; FEMALE; FIBRIN; HUMANS; MALE; PLATELET ACTIVATION; PLATELET MEMBRANE GLYCOPROTEINS; THROMBIN; THROMBOPLASTIN; THROMBOSIS;

EID: 77649207179     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.11.051     Document Type: Article

References (41)

1. Sinapius D. On parietal changes in coronary thrombosis. Remarks on frequency, origin and significance. Klin Wochenschr 43 (1965) 875-880
2. Constantinides P. Plaque fissures in human coronary thrombosis. J Atheroscler Res 6 (1966) 1-17
3. Fuster V., Moreno P.R., Fayad Z.A., Corti R., and Badimon J.J. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol 46 (2005) 937-954
4. Thim T., Hagensen M.K., Bentzon J.F., and Falk E. From vulnerable plaque to atherothrombosis. J Intern Med 263 (2008) 506-516
5. Mohler III E.R. Atherothrombosis-wave goodbye to combined anticoagulation and antiplatelet therapy?. N Engl J Med 357 (2007) 293-296
6. Eikelboom J.W., and Hirsh J. Combined antiplatelet and anticoagulant therapy: clinical benefits and risks. J Thromb Haemost 5 Suppl 1 (2007) 255-263
7. Anand S., Yusuf S., Xie C., et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 357 (2007) 217-227
8. Schneider D.J., and Sobel B.E. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation 116 (2007) 305-315
9. Carvalho A.C., Colman R.W., and Lees R.S. Platelet function in hyperlipoproteinemia. N Engl J Med 290 (1974) 434-438
10. Podrez E.A., Byzova T.V., Febbraio M., et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 13 (2007) 1086-1095
11. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 8 (2002) 1227-1234
12. Fernandez-Ortiz A., Badimon J.J., Falk E., et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 23 (1994) 1562-1569
13. van Zanten G.H., de Graaf S., Slootweg P.J., et al. Increased platelet deposition on atherosclerotic coronary arteries. J Clin Invest 93 (1994) 615-632
14. Siess W., Zangl K.J., Essler M., et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A 96 (1999) 6931-6936
15. Tedgui A., and Mallat Z. Apoptosis as a determinant of atherothrombosis. Thromb Haemost 86 (2001) 420-426
16. Rother E., Brandl R., Baker D.L., et al. Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 108 (2003) 741-747
17. Penz S., Reininger A.J., Brandl R., et al. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI. FASEB J 19 (2005) 898-909
18. Penz S.M., Reininger A.J., Toth O., Deckmyn H., Brandl R., and Siess W. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thromb Haemost 97 (2007) 435-443
19. Smethurst P.A., Joutsi-Korhonen L., O'Connor M.N., et al. Identification of the primary collagen-binding surface on human glycoprotein VI by site-directed mutagenesis and by a blocking phage antibody. Blood 103 (2004) 903-911
20. Brandl R., Richter T., Haug K., Wilhelm M.G., Maurer P.C., and Nathrath W. Topographic analysis of proliferative activity in carotid endarterectomy specimens by immunocytochemical detection of the cell cycle-related antigen Ki-67. Circulation 96 (1997) 3360-3368
21. Penz S.M. Aktivierung von Thrombozyten durch humane atherosklerotische Plaques: Mechanismen und Inhibition (2008). http://edoc.ub.uni-muenchen.de/view/autoren/Penz,_Sandra_.html Dissertation, LMU München
22. Schulz C., Penz S., Hoffmann C., et al. Platelet GPVI binds to collagenous structures in the core region of human atheromatous plaque and is critical for atheroprogression in vivo. Basic Res Cardiol 103 (2008) 356-367
23. Toth O., Calatzis A., Penz S., Losonczy H., and Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 96 (2006) 781-788
24. Hemker H.C., Al Dieri R., De Smedt E., and Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 96 (2006) 553-561
25. Ardissino D., Merlini P.A., Ariens R., Coppola R., Bramucci E., and Mannucci P.M. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 349 (1997) 769-771
26. Zillmann A., Luther T., Mueller I., et al. Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation. Biochem Biophys Res Commun 281 (2001) 603-609
27. Badimon J.J., Lettino M., Toschi V., et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 99 (1999) 1780-1787
28. Kawamoto Y., and Kaibara M. Procoagulant activity of collagen. Effect of difference in type and structure of collagen. Biochim Biophys Acta 1035 (1990) 361-368
29. Renne T., Pozgajova M., Gruner S., et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 202 (2005) 271-281
30. van der Meijden P.E., Munnix I.C., Auger J.M., et al. Dual role of collagen in factor XII-dependent thrombus formation. Blood 114 (2009) 881-890
31. Kirchhofer D., Tschopp T.B., and Baumgartner H.R. Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model. Arterioscler Thromb Vasc Biol 15 (1995) 1098-1106
32. Hoffman M., Monroe D.M., and Roberts H.R. Cellular interactions in hemostasis. Haemostasis 26 Suppl 1 (1996) 12-16
33. Reininger A.J., Reininger C.B., Heinzmann U., and Wurzinger L.J. Residence time in niches of stagnant flow determines fibrin clot formation in an arterial branching model-detailed flow analysis and experimental results. Thromb Haemost 74 (1995) 916-922
34. Munnix I.C., Strehl A., Kuijpers M.J., et al. The glycoprotein VI-phospholipase Cgamma2 signaling pathway controls thrombus formation induced by collagen and tissue factor in vitro and in vivo. Arterioscler Thromb Vasc Biol 25 (2005) 2673-2678
35. Kirchhofer D., Tschopp T.B., Steiner B., and Baumgartner H.R. Role of collagen-adherent platelets in mediating fibrin formation in flowing whole blood. Blood 86 (1995) 3815-3822
36. Furie B., and Furie B.C. Mechanisms of thrombus formation. N Engl J Med 359 (2008) 938-949
37. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24 (2004) 1015-1022
38. Butenas S., Orfeo T., and Mann K.G. Tissue factor in coagulation. Which? Where? When?. Arterioscler Thromb Vasc Biol 29 (2009) 1989-1996
39. Vanhoorelbeke K., Ulrichts H., Schoolmeester A., and Deckmyn H. Inhibition of platelet adhesion to collagen as a new target for antithrombotic drugs. Curr Drug Targets Cardiovasc Haematol Disord 3 (2003) 125-140
40. Mega J.L., Braunwald E., Mohanavelu S., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 374 (2009) 29-38
41. Nieswandt B., Schulte V., Bergmeier W., et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 193 (2001) 459-469